EDUARDO DE SOUZA MEIRELLES
Projetos de Pesquisa
Unidades Organizacionais
Instituto de Ortopedia e Traumatologia, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/41 - Laboratório de Investigação Médica do Sistema Músculoesquelético, Hospital das Clínicas, Faculdade de Medicina
LIM/41 - Laboratório de Investigação Médica do Sistema Músculoesquelético, Hospital das Clínicas, Faculdade de Medicina
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
- The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis-2019(2020) RESENDE, Gustavo Gomes; MEIRELLES, Eduardo de Souza; MARQUES, Claudia Diniz Lopes; CHIEREGHIN, Adriano; LYRIO, Andre Marun; XIMENES, Antonio Carlos; SAAD, Carla Goncalves; GONCALVES, Celio Roberto; KOHEM, Charles Lubianca; SCHAINBERG, Claudia Goldenstein; CAMPANHOLO, Cristiano Barbosa; BUENO FILHO, Julio Silvio de Sousa; PIERUCCETTI, Lenise Brandao; KEISERMAN, Mauro Waldemar; YAZBEK, Michel Alexandre; PALOMINOS, Penelope Esther; GONCALVES, Rafaela Silva Guimaraes; LAGE, Ricardo da Cruz; ASSAD, Rodrigo Luppino; BONFIGLIOLI, Rubens; ANTI, Sonia Maria Alvarenga; CARNEIRO, Sueli; OLIVEIRA, Thauana Luiza; AZEVEDO, Valderilio Feijo; BIANCHI, Washington Alves; BERNARDO, Wanderley Marques; PINHEIRO, Marcelo de Medeiros; SAMPAIO-BARROS, Percival DegravaSpondyloarthritis is a group of chronic inflammatory systemic diseases characterized by axial and/or peripheral joints inflammation, as well as extra-articular manifestations. The classification axial spondyloarthritis is adopted when the spine and/or the sacroiliac joints are predominantly involved. This version of recommendations replaces the previous guidelines published in May 2013. A systematic literature review was performed, and two hundred thirty-seven studies were selected and used to formulate 29 recommendations answering 15 clinical questions, which were divided into four sections: diagnosis, non-pharmacological therapy, conventional drug therapy and biological therapy. For each recommendation the level of evidence supporting (highest available), the strength grade according to Oxford, and the degree of expert agreement (inter-rater reliability) is informed. These guidelines bring evidence-based information on clinical management of axial SpA patients, including, diagnosis, treatment, and prognosis.
- Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis(2021) CARNEIRO, Sueli; PALOMINOS, Penelope Esther; ANTI, Sonia Maria Alvarenga; ASSAD, Rodrigo Luppino; GONCALVES, Rafaela Silva Guimaraes; CHIEREGHIN, Adriano; LYRIO, Andre Marun; XIMENES, Antonio Carlos; SAAD, Carla Goncalves; GONCALVES, Celio Roberto; KOHEM, Charles Lubianca; MARQUES, Claudia Diniz Lopes; SCHAINBERG, Claudia Goldenstein; MEIRELLES, Eduardo de Souza; RESENDE, Gustavo Gomes; PIERUCCETTI, Lenise Brandao; KEISERMAN, Mauro Waldemar; YAZBEK, Michel Alexandre; SAMPAIO-BARROS, Percival Degrava; LAGE, Ricardo da Cruz; BONFIGLIOLI, Rubens; OLIVEIRA, Thauana Luiza; AZEVEDO, Valderilio Feijo; BIANCHI, Washington Alves; BERNARDO, Wanderley Marques; SIMOES, Ricardo dos Santos; PINHEIRO, Marcelo de Medeiros; CAMPANHOLO, Cristiano BarbosaPsoriatic arthritis (PsA) is a chronic and systemic immune disease characterized by inflammation of peripheral and/or axial joints and entheses in patients with psoriasis (PsO). Extra-articular and extracutaneous manifestations and numerous comorbidities can also be present. These recommendations replace the previous version published in May 2013. A systematic review of the literature retrieved 191 articles that were used to formulate 12 recommendations in response to 12 clinical questions, divided into 4 sections: diagnosis, non-pharmacological treatment, conventional drug therapy and biologic therapy. These guidelines provide evidence-based information on the clinical management for PsA patients. For each recommendation, the level of evidence (highest available), degree of strength (Oxford) and degree of expert agreement (interrater reliability) are reported.
- Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis(2021) LAGE, Ricardo da Cruz; MARQUES, Claudia Diniz Lopes; OLIVEIRA, Thauana Luiza; RESENDE, Gustavo Gomes; KOHEM, Charles Lubianca; SAAD, Carla Goncalves; XIMENES, Antonio Carlos; GONCALVES, Celio Roberto; BIANCHI, Washington Alves; MEIRELLES, Eduardo de Souza; KEISERMAN, Mauro Waldemar; CHIEREGHIN, Adriano; CAMPANHOLO, Cristiano Barbosa; LYRIO, Andre Marun; SCHAINBERG, Claudia Goldenstein; PIERUCCETTI, Lenise Brandao; YAZBEK, Michel Alexandre; PALOMINOS, Penelope Esther; GONCALVES, Rafaela Silva Guimaraes; ASSAD, Rodrigo Luppino; BONFIGLIOLI, Rubens; LIMA, Sonia Maria Alvarenga Anti Loduca; CARNEIRO, Sueli; AZEVEDO, Valderilio Feijo; ALBUQUERQUE, Cleandro Pires; BERNARDO, Wanderley Marques; SAMPAIO-BARROS, Percival Degrava; PINHEIRO, Marcelo de MedeirosSpondyloarthritis (SpA) is a group of chronic inflammatory systemic diseases characterized by axial and/or peripheral joints inflammation, as well as extra-articular manifestations. Over some decades, nonsteroidal anti-inflammatory drugs (NSAIDs) have been the basis for the pharmacological treatment of patients with axial spondyloarthritis (axSpA). However, the emergence of the immunobiologic agents brought up the discussion about the role of NSAIDs in the management of these patients. The objective of this guideline is to provide recommendations for the use of NSAIDs for the treatment of axSpA. A panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis of randomized clinical trials for 15 predefined questions. The Grading of Recommendations, Assessment, Development and Evaluation methodology to assess the quality of evidence and formulate recommendations were used, and at least 70% agreement of the voting panel was needed. Fourteen recommendations for the use of NSAIDs in the treatment of patients with axSpA were elaborated. The purpose of these recommendations is to support clinicians' decision making, without taking out his/her autonomy when prescribing for an individual patient.